McKesson Corporation, a renowned leader in healthcare services, has released its financial results for the first quarter of fiscal year 2025, ending June 30, 2024. The company, with a rich history dating back to 1833, plays a pivotal role in the distribution of pharmaceuticals and medical supplies while providing technology solutions aimed at enhancing patient care. This report delves into the financial performance across its various segments, alongside significant highlights and challenges faced by the company during this quarter.

2. Financial Highlights

Revenue Growth

In Q1 2025, McKesson reported revenues of $79.28 billion, marking a 6% increase from $74.48 billion in Q1 2024. This growth can be attributed to solid performance across its business segments, particularly in the U.S. Pharmaceutical segment.

Net Income and Operating Profit

Net income attributable to McKesson Corporation saw a slight decline of 8%, totaling $915 million compared to $958 million in the prior year. The operating income, however, remained robust at $1.02 billion, reflecting the company's strong operational capabilities despite external challenges.

Income Statement of McKesson Corp

	Aug 2023	Aug 2024
Net Income	3.75B	2.95B
Net Income to Non-controlling Interest	160M	164M
Profit	3.91B	3.12B
Net Income Discontinued	-5M	0
Net Income Continuing	3.91B	3.12B
Income Tax Expense	800M	659M
Pretax Income	4.71B	3.78B
Non-operating Income	270M	-56M
Operating Income	4.44B	3.83B
Revenue	284.0B	313.7B
Costs and Expenses	279.5B	309.9B
Cost of Revenue	271.6B	300.7B
Operating Expenses	7.91B	9.12B
Selling, General & Administrative	7.68B	8.78B
Other Operating Expenses	225M	332M

Segment Performance

U.S. Pharmaceutical

Revenue: Increased by 7% to $4.6 billion.

Operating Profit: Decreased by 12% to $1.3 billion.

The U.S. Pharmaceutical segment continues to be the backbone of McKesson's operations, demonstrating resilience in revenue growth despite the pressures on profit margins.

Prescription Technology Solutions (RxTS)

Revenue: Decreased by 1% to $3 million.

Operating Profit: Decreased by 25% to $10 million.

The RxTS segment faced challenges related to prior gains from acquisitions, leading to a dip in performance.

Medical-Surgical Solutions

Revenue: Increased by 1% to $25 million.

Operating Profit: Decreased by 15% to $15 million.

This segment is grappling with lower demand for COVID-19 supplies, impacting its profitability.

International

Revenue: Increased by 6% to $223 million.

Operating Profit: Increased by 10% to $25 million.

The International segment exhibited strong growth, driven by higher pharmaceutical distribution volumes.

Corporate Expenses

Corporate expenses net decreased by 20% to $55 million, primarily due to a net gain related to investments in equity securities. However, this was partially offset by a charge of $55 million concerning opioid-related claims, a significant ongoing liability for the company.

3. Cash Flow Analysis

Operating activities utilized cash of $1.4 billion, reflecting a notable strain compared to $1.05 billion in the previous year. The company also repurchased 1 million shares for $528 million, reflecting its commitment to returning value to shareholders.

Cash Flow Statement of McKesson Corp

	Aug 2023	Aug 2024
Net Change in Cash	297M	-333M
Effect of Exchange Rate Changes	9M	-1M
Net Cash from Operating Activities	5.04B	3.98B
Operating Profit	3.91B	3.12B
Adjustment to Operating Profit	1.13B	863M
Net Cash from Investing Activities	-730M	-1.01B
Business & Interest in Affiliates	-10M	174M
Productive Assets	582M	730M
Other Investing Activities	-158M	-106M
Net Cash from Financing Activities	-4.03B	-3.30B
Debt	448M	-20M
Dividends	295M	322M
Equity Issuance/Repurchase	-3.23B	-2.74B
Other Financing Activities	-948M	-221M

4. Balance Sheet Overview

McKesson's total assets rose to $71.67 billion, up from $64.09 billion in the previous year. However, total liabilities also increased to $62.94 billion, resulting in a negative equity position of -$1.75 billion. The company is well-positioned with approximately $1.7 billion in cash and cash equivalents held outside of the U.S., aimed at supporting its foreign operations.

Balance Sheet of McKesson Corp

	Aug 2023	Aug 2024
Total Assets	64.09B	71.67B
Total Current Assets	45.53B	52.25B
Cash and Equivalents	2.63B	2.30B
Net Inventories	20.51B	25.57B
Prepaid Expenses	533M	636M
Total Non-current Assets	18.55B	19.41B
Intangible Assets	12.19B	12.16B
Net PP&E	2.17B	2.35B
Lease Assets	1.69B	1.73B
Other Non-current Assets	2.5B	3.16B
Total Liabilities and Equity	64.09B	71.67B
Other Equity and Liabilities	10.16B	10.10B
Total Liabilities	55.17B	62.94B
Total Current Liabilities	48.42B	56.43B
Accounts Payable and Accrued Liabilities	48.07B	56.08B
Current Debt	350M	347M
Total Non-current Liabilities	6.75B	6.51B
Long-term Debt	5.61B	5.58B
Non-current Deferred Tax Liabilities	1.13B	928M
Total Equity and Non-controlling Interests	-1.24B	-1.38B
Total Equity	-1.60B	-1.75B
Non-controlling Interests	362M	374M

5. Trends and Challenges Ahead

Despite the positive revenue growth, McKesson faces significant legal challenges related to opioid distribution claims, with an estimated liability of $6.9 billion as of June 30, 2024. The company is actively pursuing settlements but must navigate these complex legal landscapes carefully.

Furthermore, McKesson's commitment to sustainability and improving health outcomes continues to guide its strategic initiatives, as evidenced by the recent increase in its quarterly dividend from $0.62 to $0.71 per share.

6. Conclusion

As McKesson Corporation navigates the complexities of the healthcare landscape, its Q1 2025 financial results illustrate a company in transition—balancing growth with operational challenges. With a focus on enhancing shareholder value and addressing legal liabilities, McKesson remains a pivotal player in the healthcare services sector. Investors and stakeholders will be keen to monitor the company's progress as it adapts to both opportunities and challenges in the months ahead.

Original filing: sec.gov